On October 1, 2021 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentation of data on its neoantigen DNA cancer vaccine platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2021 (Press release, ImmuneTune, OCT 1, 2021, View Source [SID1234590615]). The submitted abstract was selected for a poster presentation during the SITC (Free SITC Whitepaper) conference, taking place virtually and physically in Washington, D.C., from November 10 – 14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The selected abstract is titled "Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity". Abstracts can be accessed on the SITC (Free SITC Whitepaper) website once the conference begins on November 9; posters will be presented on November 12 and 13.

"It is an exciting opportunity to present our latest preclinical data at a leading international scientific and medical conference. Building upon our publication in the journal OncoImmunology in 2019, these data now include the combination of our synthetic, linear DNA cancer vaccine platform with a novel adjuvant that targets pyroptosis to elicit a potent T cell response against tumor-specific neoantigens," stated Jeroen van Bergen, CSO of Immunetune, and presenter of the poster at SITC (Free SITC Whitepaper).